- Home
- / Coherus Oncology
Coherus Oncology
Stock Price
$0.7
2024-10-29
Market Capitalization
$85.6 M
2024-10-29
Revenue
$42.2 M
FY, 2025
Coherus Oncology Summary
Company Summary
- Overview
- Coherus BioSciences is a biopharmaceutical company that focuses on the research, development, and commercialization of cancer treatments. It offers immuno-oncology and biosimilar therapy solutions.
- Type
- Public
- Status
- Active
- Founded
- 2010
- HQ
- Redwood City, CA, US | view all locations
- Website
- https://www.coherus.com/
- Cybersecurity rating
- ESG rating
Table of Contents
Key People
Rosh Dias, Chief Medical Officer
Richard L. Hameister, Chief Technical Officer
Theresa Lavallee, Chief Development Officer
Operating MetricsView all
Patent Families
25
FY, 2020
Trials Products Approved
1
FY, 2020
Phase II Trials Products
1
FY, 2020
LocationsView all
2 locations detected
Redwood City, CA HQ
United States
333 Twin Dolphin Dr #600
Camarillo, CA
United States
1000 Avenida Acaso
Coherus Oncology Financials
Summary Financials
- Revenue (FY, 2025)
- $42.2M
- Gross profit (FY, 2025)
- $28.4M
- Net income (FY, 2025)
- $168.0M
- Cash (FY, 2025)
- $88.9M
- EBIT (FY, 2025)
- ($181.1M)
- Enterprise value
- $35.3M